The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; 35 of the 75 sources its claims cite were checked for support.
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
Open accessAbstract
Aims/hypothesis: We conducted a systematic review and network meta-analysis to compare the efficacy and safety of s.c. administered tirzepatide vs s.c. administered semaglutide for adults of both sexes with type 2 diabetes mellitus. Methods: We searched PubMed and Cochrane up to 11 November 2023 for RCTs with an intervention duration of at least 12 weeks assessing s.c. tirzepatide at maintenance doses of 5 mg, 10 mg or 15 mg once weekly, or s.c. semaglutide at maintenance doses of 0.5 mg, 1.0 mg or 2.0 mg once weekly, in adults with type 2 diabetes, regardless of background glucose-lowering treatment. Eligible trials compared any of the specified doses of tirzepatide and semaglutide against each other, placebo or other glucose-lowering drugs. Primary outcomes were changes in HbA 1c and body weight from baseline. Secondary outcomes were achievement of HbA 1c target of ≤48 mmol/mol (≤6.5%) or <53 mmol/mol (<7.0%), body weight loss of at least 10%, and safety outcomes including gastrointestinal adverse events and severe hypoglycaemia. We used version 2 of the Cochrane risk-of-bias tool (ROB 2) to assess the risk of bias, conducted frequentist random-effects network meta-analyses and evaluated confidence in effect estimates utilising the Confidence In Network Meta-Analysis (CINeMA) framework. Results: A total of 28 trials with 23,622 participants (44.2% female) were included. Compared with placebo, tirzepatide 15 mg was the most efficacious treatment in reducing HbA 1c (mean difference −21.61 mmol/mol [−1.96%]) followed by tirzepatide 10 mg (−20.19 mmol/mol [−1.84%]), semaglutide 2.0 mg (−17.74 mmol/mol [−1.59%]), tirzepatide 5 mg (−17.60 mmol/mol [−1.60%]), semaglutide 1.0 mg (−15.25 mmol/mol [−1.39%]) and semaglutide 0.5 mg (−12.00 mmol/mol [−1.09%]). In between-drug comparisons, all tirzepatide doses were comparable with semaglutide 2.0 mg and superior to semaglutide 1.0 mg and 0.5 mg. Compared with placebo, tirzepatide was more efficacious than semaglutide for reducing body weight, with reductions ranging from 9.57 kg (tirzepatide 15 mg) to 5.27 kg (tirzepatide 5 mg). Semaglutide had a less pronounced effect, with reductions ranging from 4.97 kg (semaglutide 2.0 mg) to 2.52 kg (semaglutide 0.5 mg). In between-drug comparisons, tirzepatide 15 mg, 10 mg and 5 mg demonstrated greater efficacy than semaglutide 2.0 mg, 1.0 mg and 0.5 mg, respectively. Both drugs increased incidence of gastrointestinal adverse events compared with placebo, while neither tirzepatide nor semaglutide increased the risk of serious adverse events or severe hypoglycaemia. Conclusions/interpretation: Our data show that s.c. tirzepatide had a more pronounced effect on HbA 1c and weight reduction compared with s.c. semaglutide in people with type 2 diabetes. Both drugs, particularly higher doses of tirzepatide, increased gastrointestinal adverse events. Registration: PROSPERO registration no. CRD42022382594 Graphical Abstract:
Overview
CoChat Summary
TL;DR
This systematic review and network meta-analysis of 28 RCTs (23,622 adults with type 2 diabetes) found that s.c. tirzepatide generally reduced HbA1c and body weight more than s.c. semaglutide, although all tirzepatide doses were comparable with semaglutide 2.0 mg for HbA1c when measured in mmol/mol. Both drugs increased gastrointestinal adverse events versus placebo, without increasing serious adverse events or severe hypoglycaemia.
Key findings
- In 28 RCTs with 23,622 participants (44.2% female), tirzepatide 15 mg was the most efficacious treatment for HbA1c reduction versus placebo: −21.61 mmol/mol (−1.96%), followed by tirzepatide 10 mg (−20.19 mmol/mol; −1.84%), semaglutide 2.0 mg (−17.74 mmol/mol; −1.59%), tirzepatide 5 mg (−17.60 mmol/mol; −1.60%), semaglutide 1.0 mg (−15.25 mmol/mol; −1.39%) and semaglutide 0.5 mg (−12.00 mmol/mol; −1.09%).
- For HbA1c, all tirzepatide doses were comparable with semaglutide 2.0 mg and superior to semaglutide 1.0 mg and 0.5 mg when HbA1c was measured in mmol/mol; when measured in %, tirzepatide 15 mg, 10 mg and 5 mg demonstrated greater efficacy than semaglutide 2.0 mg, 1.0 mg and 0.5 mg, respectively.
- Versus placebo, body weight reductions ranged from 9.57 kg with tirzepatide 15 mg to 5.27 kg with tirzepatide 5 mg, and from 4.97 kg with semaglutide 2.0 mg to 2.52 kg with semaglutide 0.5 mg; between-drug comparisons showed tirzepatide 15 mg, 10 mg and 5 mg were more efficacious than semaglutide 2.0 mg, 1.0 mg and 0.5 mg, respectively (MD −4.60 kg, −3.53 kg and −2.75 kg).
- Both drugs increased nausea, vomiting and diarrhoea versus placebo, and neither increased serious adverse events or severe hypoglycaemia; severe hypoglycaemia meta-analysis was not conducted because of absent events in most treatment arms.
Methods
- Systematic review and network meta-analysis of RCTs published in English, searched in PubMed and Cochrane up to 11 November 2023, including adults with type 2 diabetes and interventions of at least 12 weeks with s.c. tirzepatide 5/10/15 mg or s.c. semaglutide 0.5/1.0/2.0 mg once weekly.
- Eligible trials compared specified doses against each other, placebo or other glucose-lowering drugs that had been evaluated in at least one trial against tirzepatide and one against semaglutide; 28 trials with 23,622 participants were included.
- Frequentist random-effects network meta-analyses estimated mean differences and risk ratios with 95% CIs; risk of bias was assessed with ROB 2, confidence with CINeMA, and treatments ranked using P-scores.
Limitations
- Stated: the focused inclusion criteria are not well suited for evaluating the two medications versus common comparators; confidence was low for comparisons involving semaglutide 2.0 mg because only one RCT assessed this dose; five RCTs recruited exclusively Japanese participants, and no sex-based subgroup analyses were performed.
- Stated: long-term cardiovascular or mortality outcomes were excluded a priori because SURPASS-CVOT was ongoing; HbA1c results varied by measurement unit, with mmol/mol analyses requiring imputations or borrowing of variance values; protocol deviations included not analysing ≥5% body weight reduction and not performing planned sensitivity or subgroup analyses.
- Evident from the text: only two trials directly compared tirzepatide with semaglutide, so most comparative estimates rely on indirect evidence; 15 of the included trials were open-label.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
28 Valid · 1 Not valid · 26 Not checked · 58 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“the treatment response observed in our analysis may also be influenced by ethnic differences, given that five RCTs recruited exclusively Japanese participants [39–41, 48, 49]”
§ Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials > Discussion
What the sources say
- Supportedcites [39] Iijima T, Shibuya M, Ito Y, Terauchi Y (2023) Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: a randomized controlled trial. J Diabetes Investig 14(6):774–781. https://doi.org/10.1111/JDI.14000 source
The Study design section describes this as a randomized trial recruiting patients at a hospital in Japan, and the Discussion describes its findings as being in Japanese patients. That supports citing this paper as one of the Japanese RCTs; the suggestion that ethnicity may influence the citing authors’ analysis is their own inference, not a finding attributed to this trial. (LLM, conf=0.88)
- Supportedcites [40] Seino Y, Terauchi Y, Osonoi T et al (2018) Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab 20(2):378–388. https://doi.org/10.1111/dom.13082 source
The Trial design section describes this study as a randomized, single-country trial in Japan, and the Trial population section limits eligibility to Japanese participants. The Discussion compares its treatment responses with global trials and considers Asian–non-Asian differences, supporting the cautious suggestion that ethnicity may influence response. This source identifies one of the five cited trials; it need not establish the count of five on its own. (LLM, conf=0.92)
- Supportedcites [41] Takahashi Y, Nomoto H, Yokoyama H et al (2023) Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: a multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study). Diabetes Obes Metab 25(6):1503–1511. https://doi.org/10.1111/DOM.14998 source
The Study design and Study population sections identify SWITCH-SEMA 1 as a randomized trial enrolling Japanese patients. The Discussion states that it included only Japanese patients and that generalizability to non-Japanese patients is unknown. This supports citing it as one of the Japanese-only RCTs underlying the citing authors’ concern; the count of five belongs to the citation group, not this paper alone. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [48] Kadowaki T, Chin R, Ozeki A, Imaoka T, Ogawa Y (2022) Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol 10(9):634–644. https://doi.org/10.1016/S2213-8587(22)00187-5 source
- Not checked — no full text of the sourcecites [49] Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y (2022) Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol 10(9):623–633. https://doi.org/10.1016/S2213-8587(22)00188-7 source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“pooled data from the SURPASS clinical trial programme indicate that tirzepatide does not increase the risk of major cardiovascular events [61]”
§ Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials > Discussion
What the sources say
- Supportedcites [61] Sattar N, McGuire DK, Pavo I et al (2022) Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med 28(3):591–598. https://doi.org/10.1038/S41591-022-01707-4 source
The Discussion states that this pooled analysis of the SURPASS programme found tirzepatide was not associated with increased cardiovascular risk during a median treatment duration of just over one year. The reported MACE-4 hazard ratio was 0.80 (95% CI, 0.57–1.11), consistent with the citing sentence’s cautious wording. (LLM, conf=0.94)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the authors included only six RCTs involving tirzepatide”
§ Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials > Discussion
What the sources say
- Partly supportedcites [55] Shi Q, Nong K, Vandvik PO et al (2023) Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 381:e074068. https://doi.org/10.1136/BMJ-2022-074068 sourceExperimental — accuracy not yet measured
The Introduction says the network meta-analysis included tirzepatide, and the Results report analyses of its effects. Neither those passages nor the passages retrieved for the trial count state that exactly six tirzepatide RCTs were included; the Introduction cites five tirzepatide trials as background, not as a count of included trials. No page number is available in our copy. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Data from RCTs have consistently shown the efficacy of tirzepatide in reducing HbA1c and body weight in people with type 2 diabetes [3].”
§ Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials > Introduction
What the sources say
- Supportedcites [3] Karagiannis T, Avgerinos I, Liakos A et al (2022) Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia 65(8):1251–1261. https://doi.org/10.1007/S00125-022-05715-4 source
The Discussion reports that this meta-analysis of RCTs in people with type 2 diabetes found clinically important reductions in HbA1c and significant reductions in body weight with tirzepatide. The authors caution that the findings generalise mainly to people who are overweight or obese and receiving metformin-based background therapy. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“a benefit that was apparent regardless of the presence of type 2 diabetes”
§ Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials > Discussion
What the sources say
- Supportedcites [62] Rodriguez PJ, Goodwin Cartwright BM, Gratzl S et al (2023) Comparative effectiveness of semaglutide and tirzepatide for weight loss in adults with overweight and obesity in the US: a real-world evidence study. medRxiv 2023.11.21.23298775 (Preprint). 22 Nov 2023. Available from: https://doi.org/10.1101/2023.11.21.23298775 source
The Subgroup Analyses report significantly greater weight loss with tirzepatide in all analyses, including analyses stratified by type 2 diabetes status. The Conclusions likewise state that treatment-effect estimates were consistent in subgroups with and without type 2 diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
53 more claims · 4 with their cited sources checked
Create a free account to see all 113 claims and to verify the 2 references still open.
- Probably not a substantial claim. 31
- It may state two separate claims as one. 34
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The occurrence of such gastrointestinal side effects increases with the dose used. 86 , 87”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with preclinical and early-phase clinical trials supporting their potential as next-generation obesity treatments [16–23].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In phase 3 trials, tirzepatide decreased A1C and weight-generally to a greater extent than other glucose-lowering drugs including semaglutide and insulin-with no significant differences in the safety or efficacy in older compared with younger individuals (125).”
From 13. Older Adults: Standards of Care in Diabetes—2025 (2025) · cites this paper as [125]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The superior efficacy of tirzepatide over semaglutide observed in this real-world study aligns with findings from recent clinical trials reinforcing the potential of dual agonist therapies in obesity management [36].”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In phase 3 trials, tirzepatide decreased A1C and weight-generally to a greater extent than other glucose-lowering drugs including semaglutide and insulin-with no significant differences in the safety or efficacy in older compared with younger individuals (125).”
From 13. Older Adults: Standards of Care in Diabetes—2025 (2025) · cites this paper as [125]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials > Discussion
“Regarding trial duration, this ranged between 26 weeks and 56 weeks in all trials except for two, making a subgroup analysis based on duration unwarranted.”
§ Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials > Results > Search results and study characteristics
“The intervention duration ranged from 24 to 28 weeks in five trials and from 30 to 56 weeks in 21 trials. The remaining two trials, a trial with tirzepatide in people with obesity and type 2 diabetes (SURMOUNT-2) [50] and a cardiovascular outcomes trial with semaglutide (SUSTAIN 6) [31], had a duration of 72 and 104 weeks, respectively.”
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“For example, s.c. semaglutide has demonstrated cardiovascular benefits in the SUSTAIN-6 trial, which was designed to assess the non-inferiority of s.c. semaglutide as compared with placebo in terms of cardiovascular safety in people with type 2 diabetes at increased cardiovascular risk [31].”
Interpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884 · cited 1×
“We evaluated heterogeneity for the primary outcomes based on the agreement between CIs and prediction intervals in relation to the null effect and the clinically important effect on the opposite direction to the point estimate [16, 17].”
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521 · cited 1×
“We addressed inco-herence (inconsistency) both locally by comparing directly with indirect evidence using the Separating Indirect from Direct Evidence (SIDE) method [19] and globally using the design-by-treatment interaction model [20].”
Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
Higgins, J. P. T., Jackson, D., Barrett, J. K., Lu, G., Ades, A. E., & White, I. R. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1044 · Cited by 2,098 · cited 1×
“We addressed inco-herence (inconsistency) both locally by comparing directly with indirect evidence using the Separating Indirect from Direct Evidence (SIDE) method [19] and globally using the design-by-treatment interaction model [20].”
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 2×
“However, direct comparison between s.c. tirzepatide and s.c. semaglutide in RCTs is scarce [6, 7], presenting a challenge in drawing robust and precise conclusions regarding their comparative efficacy.”
CINeMA: an approach for assessing confidence in the results of a network meta-analysis
Nikolakopoulou, A., Higgins, J. P. T., Papakonstantinou, T., Chaimani, A., Del Giovane, C., Egger, M., & Salanti, G. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003082 · Cited by 1,935
Ranking treatments in frequentist network meta-analysis works without resampling methods
Rücker, G., & Schwarzer, G. (2015) · BMC Medical Research Methodology · doi:10.1186/s12874-015-0060-8 · Cited by 1,732 · cited 1×
“Moreover, we used P-scores, ranging from 0 to 1, to rank treatments; these can be interpreted as the average degree of certainty for a treatment to be better than the other treatments in the network [21].”
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Cited by
13. Older Adults: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s013 · Cited by 209
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Rosen, C. J., & Ingelfinger, J. R. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2500106 · Cited by 129
Xie, X., Yang, S., Deng, S., Liu, Y., Xu, Z., & He, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1613610 · Cited by 55
Psaltis, J. P., Marathe, J., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22070 · Cited by 50
Metadata
- Authors
- Karagiannis, T., Malandris, K., Avgerinos, I., Stamati, A., Kakotrichi, P., Liakos, A., Vasilakou, D., Kakaletsis, N., Tsapas, A., & Bekiari, E.
- Affiliations
- Aristotle University of Thessaloniki (GR)
- Corresponding author
- Karagiannis, Thomas
- ORCID
- Venue
- Diabetologia
- Published
- 2024-04-13
- Volume
- 67
- Issue
- 7
- Pages
- 1206-1222
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC11153294
- OpenAlex
- W4394785699
- Cited by
- 102
- References
- 62
- Citations by year
- 2026: 27 · 2025: 62 · 2024: 13
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Aristotle University of Thessaloniki
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- tirzepatide, semaglutide, type 2 diabetes, HbA1c, weight loss, gastrointestinal adverse effects, severe hypoglycemia, GLP-1 receptor agonists, antidiabetic drugs, drug efficacy and safety comparison, subcutaneous administration
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Tirzepatide, Semaglutide, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. https://app.cochat.ai/papers/10.1007/s00125-024-06144-1
- The paper
- Karagiannis, T., Malandris, K., Avgerinos, I., Stamati, A., Kakotrichi, P., Liakos, A., Vasilakou, D., Kakaletsis, N., Tsapas, A., & Bekiari, E. (2024). Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. https://doi.org/10.1007/s00125-024-06144-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.